18F-氟脱氧葡萄糖PET在靶区确定和放疗计划制定中的价值

乔文礼 ,  赵晋华

downloadPDF
文章导航 > 国际放射医学核医学杂志  > 2007,  31 > 6: (345-349)  
引用本文:
shu
Citation:
shu

18F-氟脱氧葡萄糖PET在靶区确定和放疗计划制定中的价值

  • 200080 上海, 上海交通大学附属第一人民医院核医学科

    • 通讯作者: 赵晋华, zjhl963@gmail.com

  • 中图分类号: R814.42;R817.4

18F-fluorodeoxyglucose PET in definition of target volumes and radiotherapy treatment planning

  • Department of Nuclear Medicine, The First People's Hospital, Shanghai Jiaotong University, Shanghai 200080, China

    • Corresponding author: ZHAO Jin-hua, zjhl963@gmail.com

  • CLC number: R814.42;R817.4

  • 摘要: PET是一种功能性影像技术,能够提供丰富的肿瘤生物学信息,在肿瘤靶区确定和放疗计划制定中有其应用空间。18F-氟脱氧葡萄糖(18F-FDG)具有高度的敏感性和特异性,在非小细胞肺癌、头颈部鳞状细胞癌、食管癌确定放疗靶区和制定放疗计划时具有较大作用,但尚缺乏在直肠癌等肿瘤靶区确定中的价值的相关研究。18F-FDG PET应用于放射治疗在很多方面存在问题,能否作为制定放疗计划的标准,尚无大量前瞻性临床研究,有待进一步研究和证实。
    Abstract: PET is a functional imaging modality, which can give some biological information of tumor. PET is more and more important in the definition of target volumes and radiotherapy treatment planning. Depending on its sensitivity and specificity, 18F-fluorideoxyglucose 18F-FDG PET has been shown to influence the selection of target vofumes and radiotherapy treatment planning for non-small cell lung cancers, for head and neck squamous cell carcinomas or for esophageal tumors. On the other hand, for tumors such as rectal carcinomas, convincing data on the value of 18F-FDG PET for target volume selection are still lacking. However, the application of 18F-FDG PET in many aspects of radiotherapy is still controversy. Further researches in its clinical application are still needed to investigate whether 18F-FDG PET for treatment planning should be routine because of the lack of prospective studies.
  • [1] 司宏伟,耿建华,陈盛祖.PET-CT在调强适形放疗中的临床应用.国外医学·放射医学核医学分册,2005,29(5):223-226.
    [2] Gregoire V, Haustermans K, Geets X, et al. PET-based treatment planning in radiotherapy:a new standard?. J Nucl Med, 2007, 48(Suppl 1):68S-77S.
    [3] Messa C, Di Muzio N, Picchio M, et al. PET/CT and radiotherapy. Q J Nucl Med Mol Imaging, 2006, 50(1):4-14.
    [4] Nestle U, Walter K, Schmidt S, et al.18F-Deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer:high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys, 1999, 44(3):593-597.
    [5] Erdi YE, Rosenzweig K, Erdi AK, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol, 2002, 62(1):51-60.
    [6] De Ruysscher D, Wanders S, van Haren E, et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with nonsmall-cell lung cancer:a prospective clinical study. Int J Radiat Oncol Biol Phys, 2005, 62(4):988-994.
    [7] MacManus MP, Hicks RJ, Matthews JP, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage Ⅲ nonsmall-cell lung cancer:implications for radical radiation therapy. Int J Radiat Oncol Biol Phys, 2001, 50(2):287-293.
    [8] Gondi V, Bradley K, Mehta M, et al. Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 2007, 67(1):187-195.
    [9] Deniaud-Alexandre E, Touboul E, Lerouge D, et al. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 2005, 63(5):1432-1441.
    [10] van Der Wel A, Nijsten S, Hochstenbag M, et al. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3MO non-small-cell lung cancer:a modeling study. Int J Radiat Oncol Biol Phys, 2005, 61(3):649-655.
    [11] Yaremko B, Riauka T, Robinson D, et al. Threshold modification for tumour imaging in non-small-cell lung cancer using positron emission tomography. Nucl Med Commun, 2005, 26(5):433-440.
    [12] Biehl KJ, Kong FM, Dehdashti F, et al. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer:is a single standardized uptake value threshold approach appropriate. J Nucl Med, 2006, 47(11):1808-1812.
    [13] Geets X, Daisne JF, Gregoire V, et al. Role of 11-C-methionine positron emission tomography for the delineation of the tumor volume in pharyngo-laryngeal squamous cell carcinoma:comparison with FDG-PET and CT. Radiother Oncol, 2004, 71(3):267-273.
    [14] Ciernik IF, Dizendorf E, Baumert BG, et al. Radiation treatment planning with an integrated positron emission and computer tomography(PET/CT):a feasibility study. Int J Radiat Oncol Biol Phys, 2003, 57(3):853-863.
    [15] Paulino AC, Koshy M, Howell R, et al. Comparison of CT-and FDGPET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys, 2005, 61(5):1385-1392.
    [16] Gregoire V, Daisne JF, Geets X. Comparison of CT-and FDG-PETdefined GT:in regard to Paulino et al. (Int J Radiat Oncol Biol Phys 2005;61:1385-1392). Int J Radiat Oncol Biol Phys, 2005, 63(1):308-309.
    [17] Daisne JF, Sibomana M, Bol A, et al. Tri-dimensional automatic segmentation of PET volumes based on measured source-tobackground ratios:influence of reconstruction algorithms. Radiother Oncol, 2003, 69(3):247-250.
    [18] Rahn AN, Baum RP, Adamietz IA, et al. Value of 18F -fluorodeoxyglucose positron emission tomography in radiotherapy planning of headneck tumors. Strahlenther Onkol, 1998, 174(7):358-364.
    [19] Schwartz DL, Ford E, Rajendran J, et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys, 2005, 61(1):129-136.
    [20] Schwartz DL, Ford EC, Rajendran J, et al. FDG-PET/CT-guided intensity modulated head and neck radiotherapy:a pilot investigation. Head Neck, 2005, 27(6):478-487.
    [21] Moureau-Zabotto L, Touboul E, Lerouge D, et al. Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. Int J Radiat Oncol Biol Phys, 2005, 63(2):340-345.
    [22] Vrieze O, Haustermans K, De Wever W, et al. Is there a role for FDG-PET in radiotherapy planning in esophageal carcinoma?. Radiother Oncol, 2004, 73(3):269-275.
    [23] Leong T, Everitt C, Yuen K, et al. A prospective study to evaluate the impaet of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol, 2006, 78(3):254-261.
    [24] Howard A, Mehta MP, Ritter MA, et al. The value of PET/CT in gross tumor volume delineation in lung and esophagus cancer. Int J Radiat Oncol Biol Phys, 2004, 60(Suppl):S536-S537.
    [25] Ciernik IF, Huser M, Burger C, et al. Automated functional imageguided radiation treatment planning for rectal cancer. Int J Radiat Oncol Biol Phys, 2005, 62(3):893-900.
  • [1] 吕慧清 , 张中民 , 吕仲虹 . 18F-氟代脱氧葡萄糖PET在恶性肿瘤适形放射治疗中的价值. 国际放射医学核医学杂志, 2006, 30(6): 335-337.
    [2] 李剑明 , 李亚明 . 棕色脂肪组织与18F-氟脱氧葡萄糖PET. 国际放射医学核医学杂志, 2007, 31(4): 205-207,231.
    [3] 杨吉刚 , 李春林 . 18F-氟脱氧葡萄糖PET及PET-CT在食管癌中的. 国际放射医学核医学杂志, 2007, 31(1): 31-33.
    [4] 赵德善 , 乔振华 . 18F-氟脱氧葡萄糖PET-CT在淋巴瘤中的应用价值. 国际放射医学核医学杂志, 2007, 31(3): 141-144.
    [5] 宋少莉 , 黄钢 . 18F-氟脱氧葡萄糖PET监测实体瘤放化疗疗效的应用进展. 国际放射医学核医学杂志, 2007, 31(5): 284-288.
    [6] 邢岩 , 赵晋华 . 18F-氟脱氧葡萄糖PET及PET-CT早期诊断肿瘤复发. 国际放射医学核医学杂志, 2007, 31(6): 341-344.
    [7] 渠浩 , 王振军 , 陈大志 , 王铁 , 韩进 , 杜燕夫 , 李敏哲 . 18F-氟代脱氧葡萄糖正电子放射导向手术在结直肠癌治疗中的初步应用. 国际放射医学核医学杂志, 2006, 30(3): 145-147.
    [8] 叶慧 , 莫逸 , 谢爱民 , 彭翔 . 18F-氟脱氧葡萄糖PET-CT与99nTc-亚甲基二膦酸盐骨显像诊断转移性骨肿瘤的对比研究. 国际放射医学核医学杂志, 2008, 32(3): 147-150.
    [9] 黄劲雄 , 吴华 . 功能性影像在脑胶质瘤放射治疗靶区确定中的应用. 国际放射医学核医学杂志, 2007, 31(2): 108-112.
    [10] 郑磊 , 李前伟 . 18F-氟脱氧葡萄糖PET在原发陛肝细胞癌中的应用. 国际放射医学核医学杂志, 2008, 32(1): 23-26.
    [11] 张悦 , 高硕 . 18F-氟脱氧葡萄糖PET在淋巴瘤中的应用价值. 国际放射医学核医学杂志, 2007, 31(5): 292-295.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  1391
  • HTML全文浏览量:  119
  • PDF下载量:  2
出版历程
  • 收稿日期:  2007-09-10

18F-氟脱氧葡萄糖PET在靶区确定和放疗计划制定中的价值

    通讯作者: 赵晋华, zjhl963@gmail.com
  • 200080 上海, 上海交通大学附属第一人民医院核医学科
  • 收稿日期: 2007-09-10

摘要: PET是一种功能性影像技术,能够提供丰富的肿瘤生物学信息,在肿瘤靶区确定和放疗计划制定中有其应用空间。18F-氟脱氧葡萄糖(18F-FDG)具有高度的敏感性和特异性,在非小细胞肺癌、头颈部鳞状细胞癌、食管癌确定放疗靶区和制定放疗计划时具有较大作用,但尚缺乏在直肠癌等肿瘤靶区确定中的价值的相关研究。18F-FDG PET应用于放射治疗在很多方面存在问题,能否作为制定放疗计划的标准,尚无大量前瞻性临床研究,有待进一步研究和证实。

English Abstract

    全文HTML

参考文献 (25)

目录

    /

    返回文章
    返回

    版权所有©中华医学会   备案号：津ICP备15006720号-3

    地址：天津市南开区白堤路238号电话：86-22-58089989
    86-22-85682389    传真：022-87890607

    本系统由 北京仁和汇智信息技术有限公司 开发 技术支持： info@rhhz.net